

A Real-World Data Landscape Review of the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference



Andy Surinach¹, Sushupta Vijapur¹, Ellen Thiel¹

¹Genesis Research Group; Hoboken, NJ, USA

Introduction

- Research presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conferences and published in the society's journal, *Value in Health*, offer insight into real-world data (RWD) use in the life sciences industry.
- A large proportion of abstracts submitted to the ISPOR family of conferences utilize a variety of RWD sources to generate real-world evidence.
- Regulators continue to sharpen guidance on real-world evidence, including fit-for-purpose data selection; therefore, it is important to describe the current real-world data landscape.

Objective

To quantify and characterize the RWD sources utilized for research described in ISPOR 2023 (US) conference abstracts

Methods

Data Source

- The *Value in Health* June 2023 supplemental issue, which includes all ISPOR 2023 conference abstracts, served as the source of research abstracts

Research Abstract Sample

- To identify the subset of abstracts describing RWD utilization, abstracts were filtered based a case insensitive text search of their Methods sections
- Abstracts were included if methods described direct analysis of RWD (i.e., excluding literature reviews) and identified a RWD source either by name or RWD source category

Search Terms




"database", "data base", "real world", "real-world", "claims", "electronic health", "real-world data", "linked", "token", "survey", "registry", "electronic medical", "ehr", "emr"

- Abstracts that included these search terms were included in the sample for additional manual review by two reviewers
- Reviewers documented the RWD source characteristics from each abstract including:
 - RWD Source Name
 - RWD Source Type (e.g., administrative claims)
 - Country
 - Tokenized / Linked Data Source

Statistical Analyses

- Abstract characteristics were summarized with descriptive statistics


Figure 1. Abstract Selection



Results


- Among the 1,816 ISPOR abstracts presented at ISPOR 2023, 834 (46%) mentioned utilization of RWD, and 505 met inclusion criteria for RWD source description **Figure 1**
- A total of 165 unique RWD sources were cited in the N=505 abstracts
- The most common RWD source type utilized for research was administrative claims (N=259 abstracts (51%)) **Figure 2**
- The majority of RWD sources were from the U.S. (N=429 abstracts; 85%)
- Ex-U.S. sources were rarely used for this U.S.-based conference (Range: 1-15) **Figure 3**

Figure 2. RWD Sources Utilized for Research in ISPOR 2023 Abstracts by Type



- A total of 16 (3.2%) abstracts cited utilizing multiple RWD sources, for example:
 - The combination of administrative claims with survey data
 - The combination of a disease specific EHR linked to closed and open claims through tokenization

Figure 3. RWD Sources by Geography



Limitations

- Our search terms may have omitted non-standard RWD sources from the manually reviewed abstract sample.
- Descriptions of the RWD sources and/or specific data source names may have been abbreviated due to abstract word limits.

Conclusions

- RWD is an essential resource for the life sciences industry.
- Administrative claims remain the most utilized source; however, these data may not contain variables required for all RWE research questions.
- Given the abundance of current RWD options, each with unique strengths and limitations, a broad and current understanding of the RWD landscape and a data source agnostic strategy are beneficial for selecting fit-for-purpose RWD.

Disclosures

This study was conducted by Genesis Research Group and all authors are employees of Genesis Research Group.



Scan the QR code to obtain a copy of this poster.